Newborns, particularly premature infants, often face complex medical issues that require immediate and effective treatment. The pharmacokinetics and pharmacodynamics in neonates differ significantly from adults and older children, making it challenging to apply existing drug data directly. Due to the ethical and practical difficulties in conducting clinical trials in this population, many healthcare providers rely on off-label use to manage life-threatening conditions.